Clinical Trials Browser

Active not recruiting × OTHER × Fulvestrant × Clear all

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT03531645 2026-03-05

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

Phase 2 Active not recruiting

Malignant Neoplasms of Female Genital Organs

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT01953588 2026-01-22

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Phase 3 Active not recruiting

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03393845 2026-01-02

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Phase 2 Active not recruiting

Breast Neoplasms

NCT04762979 2026-01-02

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Phase 2 Active not recruiting

Hormone Receptor Positive Breast Carcinoma

NCT02738866 2025-12-10

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Phase 2 Active not recruiting

Breast Neoplasms

NCT05090358 2025-10-27

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 2 Active not recruiting

220 enrolled 11 charts

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Phase 1 Active not recruiting

Breast Neoplasms

NCT05063786 2025-09-08

ALPHABET

Phase 3 Active not recruiting

Breast Neoplasms

NCT05625087 2025-08-20

SAFIR 03

Phase 2 Active not recruiting

Breast Neoplasms

NCT00585507 2025-07-10

Efficacy and Safety of 500mg of Fulvestrant

Phase 2 Active not recruiting

Breast Neoplasms

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Phase 2 Active not recruiting

61 enrolled 12 charts

Breast Neoplasms

NCT05463601 2025-05-14

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

Phase 3 Active not recruiting

Breast Neoplasms

NCT04053322 2025-03-12

DOLAF

Phase 2 Active not recruiting

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms

NCT02792465 2024-01-17

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms